Suppr超能文献

COVID-19 无已知动脉粥样硬化疾病患者的冠状动脉钙化与 6 个月死亡率。

Coronary artery calcifications and 6-month mortality in patients with COVID-19 without known atheromatous disease.

机构信息

Faculté de médecine, Sorbonne université, 75006 Paris, France.

Faculté de médecine, université de Paris, 75006 Paris, France; Institut national de la santé et de la recherche médicale, PARCC, UMR970, 75015 Paris, France; CIC1418 and DMU CARTE, hôpital européen Georges-Pompidou, AP-HP, 75015 Paris, France.

出版信息

Arch Cardiovasc Dis. 2022 May;115(5):276-287. doi: 10.1016/j.acvd.2022.02.007. Epub 2022 Mar 4.

Abstract

BACKGROUND

Coronary artery calcium (CAC) is an independent risk factor for major adverse cardiovascular events; however, its impact on coronavirus disease 2019 (COVID-19) mortality remains unclear, especially in patients without known atheromatous disease.

AIMS

To evaluate the association between CAC visual score and 6-month mortality in patients without history of atheromatous disease hospitalized with COVID-19 pneumonia.

METHODS

A single-centre observational cohort study was conducted, involving 293 consecutive patients with COVID-19 in Paris, France, between 13 March and 30 April 2020, with a 6-month follow-up. Patients with a history of ischaemic stroke or coronary or peripheral artery disease were excluded. The primary outcome was all-cause mortality at 6 months according to CAC score, which was assessed by analysing images obtained after the first routine non-electrocardiogram-gated computed tomography scan performed to detect COVID-19 pneumonia.

RESULTS

A total of 251 patients (mean age 64.8±16.7 years) were included in the analysis. Fifty-one patients (20.3%) died within 6 months. The mortality rate increased with the magnitude of calcifications, and was 10/101 (9.9%), 15/66 (22.7%), 10/34 (29.4%) and 16/50 (32.0%) for the no CAC, mild CAC, moderate CAC and heavy CAC groups, respectively (p=0.004). Compared with the no calcification group, adjusted risk of death increased progressively with CAC: hazard ratio (HR) 2.37 (95% confidence interval [CI] 1.06-5.27), HR 3.1 (95% CI 1.29-7.45) and HR 4.02 (95% CI 1.82-8.88) in the mild, moderate and heavy CAC groups, respectively.

CONCLUSIONS

Non-electrocardiogram-gated computed tomography during the initial pulmonary assessment of patients with COVID-19 without atherosclerotic cardiovascular disease showed a high prevalence of mild, moderate and heavy CAC. CAC score was related to 6-month mortality, independent of conventional cardiovascular risk factors. These results highlight the importance of CAC scoring for patients hospitalized with COVID-19, and calls for attention to patients with high CAC.

摘要

背景

冠状动脉钙(CAC)是主要不良心血管事件的独立危险因素;然而,其对 2019 年冠状病毒病(COVID-19)死亡率的影响尚不清楚,尤其是在没有已知动脉粥样硬化疾病的患者中。

目的

评估无动脉粥样硬化疾病史的 COVID-19 肺炎住院患者 CAC 视觉评分与 6 个月死亡率之间的关系。

方法

这是一项单中心观察性队列研究,纳入了 2020 年 3 月 13 日至 4 月 30 日期间在法国巴黎的 293 例连续 COVID-19 患者,随访 6 个月。排除有缺血性卒中或冠状动脉或外周动脉疾病史的患者。主要结局是根据 CAC 评分评估的 6 个月时全因死亡率,CAC 评分通过分析首次为检测 COVID-19 肺炎而进行的常规非心电图门控计算机断层扫描后的图像来评估。

结果

共有 251 例患者(平均年龄 64.8±16.7 岁)纳入分析。51 例患者(20.3%)在 6 个月内死亡。死亡率随钙化程度的增加而增加,无 CAC、轻度 CAC、中度 CAC 和重度 CAC 组的死亡率分别为 10/101(9.9%)、15/66(22.7%)、10/34(29.4%)和 16/50(32.0%)(p=0.004)。与无钙化组相比,CAC 与死亡风险逐渐增加相关:轻度 CAC 组、中度 CAC 组和重度 CAC 组的风险比(HR)分别为 2.37(95%置信区间[CI] 1.06-5.27)、3.1(95% CI 1.29-7.45)和 4.02(95% CI 1.82-8.88)。

结论

在无动脉粥样硬化性心血管疾病的 COVID-19 患者的初始肺部评估期间进行非心电图门控计算机断层扫描,显示出轻度、中度和重度 CAC 的高患病率。CAC 评分与 6 个月死亡率相关,独立于传统心血管危险因素。这些结果突出了 CAC 评分对 COVID-19 住院患者的重要性,并呼吁关注 CAC 较高的患者。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/1894/8895715/da8d53c7d9ed/gr1_lrg.jpg

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验